Monday, September 30, 2019

Ranitidine controversy: Which Indian pharma companies stand to lose?

Ranitidine controversy: Which Indian pharma companies stand to lose? NULL

from Moneycontrol Business News https://ift.tt/2nRJ8ks

No comments:

Post a Comment

Vijay Kedia-backed cybersecurity stock announces 1:1 bonus issue. Check details

Shares of Vijay Kedia-backed TAC Infosec rose on news of a one-for-one bonus issue, backed by strong financial performance, including a 157%...